Latest Period
Q4 2025
Security Snapshot
ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) Institutional Ownership
CUSIP: H0036K147
13F Institutional Holders and Ownership History from Q2 2020 to Q1 2026
Institutions Reporting
114
Shares (Excl. Options)
82,866,357
Price
$3.53
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Shares, par value CHF 0.08 per share
- Symbol
- ADCT on NYSE
- Shares outstanding
- 128,459,465
- Price per share
- $3.78
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 82,866,357
- Total reported value
- $292,847,531
- % of total 13F portfolios
- 0%
- Share change
- +14,892,279
- Value change
- +$51,266,770
- Number of holders
- 114
- Price from insider filings
- $3.78
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- ADCT - ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share is tracked under CUSIP H0036K147.
- 114 institutions reported positions in Q4 2025.
- 8 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 114 to 18 between Q4 2025 and Q1 2026.
- Reported value moved from $292,847,531 to $1,929,157.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 114 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP H0036K147?
CUSIP H0036K147 identifies ADCT - ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP H0036K147:
Significant Owners of ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Redmile Group, LLC | 9.9% | 0% | $47,690,576 | +$92,422 | 12,717,487 | +0.19% | Redmile Group, LLC | 20 Apr 2026 |
| TCG Crossover GP II, LLC | 9.2% | $42,143,648 | 11,390,175 | TCG Crossover GP II, LLC | 27 Oct 2025 | |||
| HPWH TH AG | 9.6% | $14,291,858 | 9,788,944 | Dr. Hans-Peter Wild | 15 May 2025 | |||
| Prosight Management, LP | 6.8% | +17% | $31,366,151 | +$4,743,267 | 8,477,338 | +18% | Prosight Management, LP | 31 Dec 2025 |
| Point72 Asset Management, L.P. | 4% | -43% | $18,554,083 | -$10,422,190 | 5,014,617 | -36% | Point72 Asset Management, L.P. | 31 Dec 2025 |
| BlackRock, Inc. | 5% | -4% | $7,173,203 | -$144,108 | 4,913,153 | -2% | BlackRock, Inc. | 31 Mar 2025 |
| Oaktree Capital Group Holdings GP, LLC | 4.1% | $18,693,764 | 4,673,441 | Oaktree Fund Administration, LLC | 30 Sep 2025 | |||
| ORBIMED ADVISORS LLC | 2.6% | -25% | $11,953,949 | -$765,959 | 3,230,797 | -6% | ORBIMED CAPITAL LLC | 31 Dec 2025 |
As of 31 Dec 2025, 114 institutional investors reported holding 82,866,357 shares of ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT). This represents 65% of the company’s total 128,459,465 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) together control 60% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Redmile Group, LLC | 12% | 15,666,731 | 0% | 4.1% | $55,303,560 |
| TCG Crossover Management, LLC | 8.9% | 11,390,175 | +719% | 1.3% | $40,207,318 |
| Prosight Management, LP | 6.6% | 8,477,338 | +13% | 6.2% | $29,925,003 |
| ORBIMED ADVISORS LLC | 4.5% | 5,822,854 | -1.4% | 0.44% | $20,554,675 |
| Nantahala Capital Management, LLC | 4.3% | 5,475,433 | +142% | 1.2% | $19,328,279 |
| BlackRock, Inc. | 4.2% | 5,427,309 | +20% | 0% | $19,158,401 |
| Point72 Asset Management, L.P. | 3.9% | 5,014,617 | -38% | 0.03% | $17,701,598 |
| MORGAN STANLEY | 2.9% | 3,769,743 | +2.7% | 0% | $13,307,192 |
| EVENTIDE ASSET MANAGEMENT, LLC | 2.6% | 3,364,067 | 0.19% | $11,875,157 | |
| GOLDMAN SACHS GROUP INC | 1.3% | 1,640,872 | +2.9% | 0% | $5,792,278 |
| STATE STREET CORP | 1.1% | 1,407,325 | +8.6% | 0% | $4,967,857 |
| BANK OF AMERICA CORP /DE/ | 1% | 1,298,584 | -4.6% | 0% | $4,584,002 |
| VANGUARD GROUP INC | 0.88% | 1,129,587 | +90% | 0% | $3,987,442 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.78% | 996,523 | +15% | 0% | $3,517,725 |
| PLATINUM INVESTMENT MANAGEMENT LTD | 0.77% | 990,778 | -14% | 0.81% | $3,497,446 |
| BNP PARIBAS FINANCIAL MARKETS | 0.65% | 830,903 | 0% | 0% | $2,933,088 |
| Blue Owl Capital Holdings LP | 0.57% | 733,568 | 0% | 0.91% | $2,934,272 |
| Vantage Consulting Group Inc | 0.53% | 682,998 | 0% | 12% | $2,410,983 |
| PANAGORA ASSET MANAGEMENT INC | 0.46% | 594,256 | +9.2% | 0.01% | $2,097,724 |
| ACADIAN ASSET MANAGEMENT LLC | 0.41% | 528,965 | +133% | 0% | $1,860,000 |
| STEMPOINT CAPITAL LP | 0.39% | 502,570 | +77% | 0.3% | $1,774,072 |
| JPMORGAN CHASE & CO | 0.37% | 471,693 | +43% | 0% | $1,665,076 |
| Voleon Capital Management LP | 0.36% | 464,159 | +560% | 0.04% | $1,638,481 |
| NORTHERN TRUST CORP | 0.34% | 437,551 | +4.8% | 0% | $1,544,556 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | 0.33% | 418,782 | 0% | $1,465,737 |
Institutional Holders of ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 514,244 | $1,929,157 | +$28,600 | $3.75 | 18 |
| 2025 Q4 | 82,866,357 | $292,847,531 | +$51,266,770 | $3.53 | 114 |
| 2025 Q3 | 68,158,412 | $272,625,712 | -$9,526,921 | $4.00 | 105 |
| 2025 Q2 | 67,952,003 | $182,114,158 | +$35,606,077 | $2.68 | 84 |
| 2025 Q1 | 54,846,167 | $77,332,587 | -$2,528,133 | $1.41 | 82 |
| 2024 Q4 | 56,494,277 | $112,422,732 | -$3,041,138 | $1.99 | 82 |
| 2024 Q3 | 54,883,537 | $172,881,709 | +$3,394,419 | $3.15 | 76 |
| 2024 Q2 | 51,801,951 | $163,693,841 | +$51,364,315 | $3.16 | 73 |
| 2024 Q1 | 34,683,534 | $155,728,721 | +$7,168,355 | $4.49 | 36 |
| 2023 Q4 | 33,953,461 | $56,361,695 | -$3,915,509 | $1.66 | 36 |
| 2023 Q3 | 39,458,503 | $35,390,528 | -$10,272,333 | $0.90 | 40 |
| 2023 Q2 | 45,357,348 | $97,515,460 | -$1,939,928 | $2.15 | 55 |
| 2023 Q1 | 46,611,135 | $90,890,151 | +$6,156,453 | $1.95 | 57 |
| 2022 Q4 | 38,834,584 | $149,117,927 | +$3,712,534 | $3.84 | 59 |
| 2022 Q3 | 36,621,247 | $176,523,672 | +$9,038,590 | $4.82 | 60 |
| 2022 Q2 | 34,475,113 | $274,062,429 | +$4,571,679 | $7.95 | 52 |
| 2022 Q1 | 34,123,674 | $501,279,862 | +$2,970,760 | $14.69 | 44 |
| 2021 Q4 | 33,799,357 | $682,750,000 | +$19,180,842 | $20.20 | 50 |
| 2021 Q3 | 32,792,604 | $890,647,136 | -$45,594,727 | $27.16 | 51 |
| 2021 Q2 | 33,533,099 | $816,251,800 | +$17,173,667 | $24.35 | 53 |
| 2021 Q1 | 32,826,058 | $801,283,858 | +$19,636,706 | $24.41 | 55 |
| 2020 Q4 | 32,141,073 | $1,028,835,000 | +$31,200,598 | $32.01 | 51 |
| 2020 Q3 | 28,226,306 | $921,776,783 | +$216,837,760 | $32.99 | 51 |
| 2020 Q2 | 21,557,623 | $1,000,339,109 | +$1,000,339,111 | $46.81 | 41 |